Of 14 prespecified secondary outcomes , 9 were analyzed , including asthma exacerbation ; of those 9 , the only statistically significant outcome was a small difference in the overall dose of ciclesonide required to maintain asthma control ( 111.3 g/d [ 95 % CI , 102.2-120 .4 g/d ] in the vitamin D3 group vs 126.2 g/d [ 95 % CI , 117.2-135 .3 g/d ] in the placebo group ; difference of 14.9 g/d [ 95 % CI , 2.1-27 .7 g/d ] ) .